image
Technology - Software - Application - NASDAQ - US
$ 35.45
2.13 %
$ 5.62 B
Market Cap
-122.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one VERX stock under the worst case scenario is HIDDEN Compared to the current market price of 35.5 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one VERX stock under the base case scenario is HIDDEN Compared to the current market price of 35.5 USD, Vertex, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 7, 2025.

The intrinsic value of one VERX stock under the best case scenario is HIDDEN Compared to the current market price of 35.5 USD, Vertex, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VERX

image
$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
667 M REVENUE
16.49%
-2.23 M OPERATING INCOME
69.99%
-52.7 M NET INCOME
-302.73%
165 M OPERATING CASH FLOW
121.74%
-158 M INVESTING CASH FLOW
-139.00%
231 M FINANCING CASH FLOW
973.26%
177 M REVENUE
-0.78%
4.49 M OPERATING INCOME
134.23%
11.1 M NET INCOME
116.42%
14.8 M OPERATING CASH FLOW
-64.01%
-17.8 M INVESTING CASH FLOW
28.28%
-20.7 M FINANCING CASH FLOW
-330.34%
Balance Sheet Vertex, Inc.
image
Current Assets 536 M
Cash & Short-Term Investments 305 M
Receivables 164 M
Other Current Assets 66.7 M
Non-Current Assets 630 M
Long-Term Investments 0
PP&E 190 M
Other Non-Current Assets 441 M
26.16 %14.09 %5.72 %16.24 %37.79 %Total Assets$1.2b
Current Liabilities 537 M
Accounts Payable 36.2 M
Short-Term Debt 4.07 M
Other Current Liabilities 497 M
Non-Current Liabilities 450 M
Long-Term Debt 348 M
Other Non-Current Liabilities 102 M
3.67 %50.34 %35.22 %10.35 %Total Liabilities$987.4m
EFFICIENCY
Earnings Waterfall Vertex, Inc.
image
Revenue 667 M
Cost Of Revenue 241 M
Gross Profit 426 M
Operating Expenses 428 M
Operating Income -2.23 M
Other Expenses 50.5 M
Net Income -52.7 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)667m(241m)426m(428m)(2m)(51m)(53m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
63.91% GROSS MARGIN
63.91%
-0.33% OPERATING MARGIN
-0.33%
-7.91% NET MARGIN
-7.91%
-29.40% ROE
-29.40%
-4.52% ROA
-4.52%
9.71% ROIC
9.71%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Vertex, Inc.
image
100m100m90m90m80m80m70m70m60m60m50m50m40m40m30m30m20m20m10m10m0020192019202020202021202120222022202320232024202420252025
Net Income -52.7 M
Depreciation & Amortization 86.7 M
Capital Expenditures -65.8 M
Stock-Based Compensation 47.4 M
Change in Working Capital 0
Others 32.3 M
Free Cash Flow 99.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Vertex, Inc.
image
Wall Street analysts predict an average 1-year price target for VERX of $50 , with forecasts ranging from a low of $37 to a high of $62 .
VERX Lowest Price Target Wall Street Target
37 USD 4.37%
VERX Average Price Target Wall Street Target
50 USD 41.04%
VERX Highest Price Target Wall Street Target
62 USD 74.89%
Price
Max Price Target
Min Price Target
Average Price Target
65656060555550504545404035353030Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Vertex, Inc.
image
Sold
0-3 MONTHS
45.5 M USD 4
3-6 MONTHS
5.62 M USD 2
6-9 MONTHS
278 M USD 8
9-12 MONTHS
70.9 M USD 6
Bought
0 USD 0
0-3 MONTHS
299 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older. zacks.com - 6 days ago
Vertex's next-generation cystic fibrosis drug gets EU approval Vertex said on Tuesday that its next-generation drug, Alyftrek, gained European Commission approval for the treatment of cystic fibrosis. reuters.com - 1 week ago
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from this new, once-daily medicine, which has demonstrated further. businesswire.com - 1 week ago
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to hold. zacks.com - 1 week ago
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea BOSTON & OSAKA, Japan--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential b. businesswire.com - 2 weeks ago
Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 FORWARD-101 clinical trial of zimislecel (VX-880), an investigational stem cell-derived, fully differentiated islet cell therapy, in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs). The data were featured in an oral presentation at the Americ. businesswire.com - 2 weeks ago
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year's E. businesswire.com - 1 month ago
Targeting The NaV1.8 Pathway In Pain Management: Eli Lilly And Vertex Lead The Way Both Vertex and Eli Lilly are entering the non-opioid pain management market, targeting the promising $20B+ opportunity. Vertex's Journavx, targeting NaV1.8, is FDA-approved and shows opioid-level pain relief with fewer side effects, positioning it as a potential new standard of care. Eli Lilly's acquisition of SiteOne Therapeutics and STC-004 brings a once-daily NaV1.8 candidate, with early promising results but limited clinical data so far. seekingalpha.com - 1 month ago
Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline? Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends Vertex's CF leadership, patent life, and addressable market, while Casgevy and Journavx add new growth avenues. VRTX valuation is justified by stable CF cash flows, a strong balance sheet, proven management, and a diversified pipeline with multiple near-term catalysts. seekingalpha.com - 1 month ago
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Vertex Energy, Inc. Common Stock - VTNRQ HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court, Southern District of Texas, Houston Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Vertex Energy, Inc. common stock (OTCMKTS: VTNRQ): globenewswire.com - 1 month ago
Vertex to Participate in Upcoming Investor Conferences BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in the Evercore Biotechnology Summit on Wednesday, May 21, 2025. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Bernstein 41st Annual Strategic Decisions. businesswire.com - 1 month ago
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft The Investment Committee give you their top names to watch for the second half. youtube.com - 1 month ago
8. Profile Summary

Vertex, Inc. VERX

image
COUNTRY US
INDUSTRY Software - Application
MARKET CAP $ 5.62 B
Dividend Yield 0.00%
Description Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Contact 2301 Renaissance Boulevard, King of Prussia, PA, 19406 https://www.vertexinc.com
IPO Date July 29, 2020
Employees 1900
Officers Mr. David DeStefano Chief Executive Officer, President & Chairman of the Board Mr. Bryan T. R. Rowland Senior Vice President, General Counsel & Secretary Mr. Salvatore Visca Chief Technology Officer Mr. Ben Askin Chief Information Officer Mr. Ryan J. Leib CPA Chief Accounting Officer Mr. Ray Westphal Founder Ms. Stefanie Westphal-Lucas Thompson Co-Owner & Independent Director Mr. John R. Schwab Chief Financial Officer Mr. Steven Hinckley Chief Operating Officer Ms. Amanda Westphal Radcliffe Co-Owner & Independent Director